IP Library Granted Patent US 6,870,045
Granted Patent B2
US 6,870,045 · App. 10/001,407 · Granted Mar 22, 2005

Kits for detecting HIV-2

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,870,045
App. No.
10/001,407
Granted
Mar 22, 2005
Kind
B2
Abstract

Compositions and methods for synthesizing and detecting HIV-2 specific amplicons. Particularly described are oligonucleotides that are useful as hybridization probes, and amplification primers that facilitate detection of very low levels of HIV-2 nucleic acids.

Claims (34)

1. A kit for detecting HIV-2 nucleic acids, comprising a packaged combination of the following components in one or more containers:

(a) a first amplification oligonucleotide that consists of SEQ ID NO:10 and optionally comprises a 5′ promoter sequence non-complementary to the HIV-2 nucleic acid; and

(b) a second amplification oligonucleotide comprising a sequence of 19-40 contiguous bases from the sequence of SEQ ID NO:1, said second amplification oligonucleotide having a length of up to 100 nucleotides.

2. The kit of claim 1 , further comprising:

(c) an oligonucleotide detection probe that comprises the sequence of SEQ ID NO:21 or the complement thereof, and a detectable label.

3. The kit of claim 1 , wherein the length of the second amplification oligonucleotide is 19-40 nucleotides.

4. The kit of claim 3 , wherein the length of the first amplification oligonucleotide is up to 60 nucleotides.

5. The kit of claim 3 , wherein the length of the first amplification oligonucleotide is up to 60 nucleotides, wherein the first amplification oligonucleotide includes said optional 5′ promoter sequence.

6. The kit of claim 3 , wherein the length of the second amplification oligonucleotide is 19-21 nucleotides.

7. The kit of claim 4 , wherein the length of the second amplification oligonucleotide is 19-21 nucleotides.

8. The kit of claim 5 , wherein the first amplification oligonucleotide is the promoter-primer of SEQ ID NO:15.

9. The kit of claim 7 , wherein the second amplification oligonucleotide is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7.

10. The kit of claim 7 , wherein the first amplification oligonucleotide includes said optional 5′ promoter sequence.

11. The kit of claim 10 , wherein the first amplification oligonucleotide is the promoter-primer of SEQ ID NO:15.

12. The kit of claim 10 , wherein the second amplification oligonucleotide is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7.

13. The kit of claim 11 , wherein the second amplification oligonucleotide is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7.

14. The kit of claim 11 , wherein the length of the first amplification oligonucleotide is 25 nucleotides, and wherein the length of the second amplification oligonucleotide is 19-21 nucleotides.

15. The kit of claim 14 , wherein the second amplification oligonucleotide is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7.

16. The kit of claim 14 , wherein the second amplification oligonucleotide is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7.

17. The kit of claim 2 , wherein said oligonucleotide detection probe has a length of up to 18 nucleotides.

18. The kit of claim 17 , wherein the sequence of said oligonucleotide detection probe is selected from the group consisting of SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26 and SEQ ID NO:27.

19. The kit of claim 18 , wherein the sequence of the first amplification oligonucleotide is SEQ ID NO:10 or SEQ ID NO:15, wherein the sequence of the second amplification oligonucleotide is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7, and wherein the sequence of the oligonucleotide detection probe is selected from the group consisting of SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26 and SEQ ID NO:27.

20. The kit of claim 2 , wherein said oligonucleotide detection probe has a length of up to 35 nucleotides.

21. The kit of claim 20 , wherein the length of said oligonucleotide detection probe is up to 22 nucleotides.

22. The kit of claim 21 , wherein said oligonucleotide detection probe comprises at least 16 contiguous nucleotides contained within the sequence of SEQ ID NO:20 or the complement thereof.

23. The kit of claim 22 , wherein said oligonucleotide detection probe has the sequence of SEQ ID NO:20 or the complement thereof.

24. The kit of claim 22 , wherein said oligonucleotide detection probe has a length of up to 18 nucleotides.

25. The kit of claim 24 , wherein the length of said oligonucleotide detection probe is 18 nucleotides.

26. The kit of claim 24 , wherein said oligonucleotide detection probe has a sequence selected from the group consisting of SEQ ID NO:22 or the complement thereof, SEQ ID NO:23 or the complement thereof, SEQ ID NO:24 or the complement thereof, SEQ ID NO:25 or the complement thereof, SEQ ID NO:26 or the complement thereof, and SEQ ID NO:27 or the complement thereof.

27. The kit of claim 20 , wherein said oligonucleotide detection probe comprises DNA.

28. The kit of claim 20 , wherein said oligonucleotide detection probe comprises at least one nucleotide analog.

29. The kit of claim 28 , wherein said at least one nucleotide analog comprises a methoxy group at the 2′ position of a ribose moiety.

30. The kit of claim 26 , wherein the detectable label is a chemiluminescent label or a radiolabel.

31. The kit of claim 30 , wherein the detectable label is an acridinium ester.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →